Why the study?
Does continuous intravenous iloprost improve exercise tolerance compared to epoprostenol in patients with severe pulmonary hypertension?
Population
8 patients with severe pulmonary hypertension (5 primary, 3 thromboembolic)
Comparison
Continuous intravenous iloprost for 3 to 6 weeks vs Continuous intravenous epoprostenol for 3 to 6…
Design
Other
Follow-up
3 to 6 weeks per phase
Authors
Loading...
Iloprost-associated walking gains in severe PH; hypothesis-generating versus epoprostenol, requiring randomized confirmation before practice change.
Does continuous intravenous iloprost improve exercise tolerance compared to epoprostenol in patients with severe pulmonary hypertension?
Continuous intravenous iloprost significantly improves exercise tolerance in patients with severe pulmonary hypertension, offering an effective alternative to epoprostenol.
Higenbottam et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: